Not currently recruiting at UC Health
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCSD
- Dates
- study startedestimated completion
- Principal Investigator
- by Ayad Hamdan, MD (ucsd)Elizabeth Brem, MD (uci)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at UC Health
- Ayad Hamdan, MD (ucsd)
Associate Clinical Professor, Medicine. - Elizabeth Brem, MD (uci)
Assistant Health Sciences Professor, Medicine. Authored (or co-authored) 9 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Karyopharm Therapeutics Inc
- ID
- NCT04607772
- Phase
- Phase 1/2
- Study Type
- Interventional
- Last Updated